Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Low Intensity Laser Therapy on Immune System Response Among Children With Pneumonia

NCT07552116 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-04-06
Last updated
2026-04-27

Condition(s) studied

Pneumonia

Investigational drug(s) / intervention(s)

low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurementsreceived inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.

low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements: low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements

received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.: received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.

Study summary

Objective: The aim of this study was to detect the impact of low intensity laser therapy on immune system response among DS children with pneumonia. Material and Methods: Forty DS children with bronchopneumonia, were included into ; group (A) received low intensity laser therapy, inspiratory muscle training in addition to medical treatment at a frequency of 3 sessions per week for one month, where the second group (B) received inspiratory muscle training in addition to medical treatment. Measurements of WBCs, IgG, IgA, IgM, RR and SaO2 were obtained for both groups before treatment and after one month at the end of the treatment program.

Eligibility

Sex
ALL
Min age
3 Years
Max age
5 Years
Healthy volunteers
No
Inclusion Criteria: * Dawn Syndrome children with pneumonia * Mean age of 3.73±1.82 year * Children were in the first attack of bronchopneumonia. Exclusion Criteria: * Other chest disease

Primary outcome measure(s)

  • IgG — at baseline and after one month
    Immunoglobulin-G (mg/dl)
  • IgA — at baseline and after one month
    Immunoglobulin-A(mg/dl)
  • IgM — at baseline and after one month
    Immunoglobulin-M (mg/dl)
  • WBCs — at baseline and after one month
    White blood cells (thousands/mm3)

Trial sites (1)

FacilityCityRegionStatus
Mona Mohamed Abdelkhalek Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07552116 on ClinicalTrials.gov ↗ ← All trials in Egypt